Global licence agreements, collaboration agreements and fundraising mandates are among the areas of activity for the Cambridge-based life sciences team at Mills & Reeve LLP. James Fry heads the practice and has expertise in intellectual property licensing work and regulatory issues such as clinical trials. His Cambridge colleague Kevin Calder's practice centres on commercial contracts and procurement. Research and development agreements fall within the purview of Stephanie Caird's practice. Isabel Teare is a further name to note.
Legal 500 Editorial commentary
Key clients
- GSK
- Illumina
- CMR Surgical
- Neurocrine Biosciences
- F-star Therapeutics
- Coloplast
- NRG Therapeutics
- PhoreMost
- Instil Bio
- Calypso Biotech
- Sphere Fluidics
- Sanger Institute
- Wavebreak Therapeutics
- Mission Therapeutics
- Oxford Biomedica
- ImmuOne
- Kadans
- Amano Enzyne
- Rinri Therapeutics
- RNAvate
- Pivotal Earth
Work highlights
- Advised F-star Therapeutics on its strategic discovery collaboration and licence agreement with global pharmaceutical company Takeda. Also advised F-star on its second licence agreement with Takeda for the further development of a novel next-generation immuno-oncology bispecific antibody.
- Advised Orbit Service Partners Inc., an emerging provider of innovative solutions in the field of public health, on a groundbreaking licence and collaboration agreement with Verily, an Alphabet precision health technology company based in South San Francisco, USA, to introduce the Debug programme in Barbados and the Caribbean.
- Acted for Autolus Therapeutics Limited on the grant of a lease of Nucleus, Stevenage from Forge Life Sciences (a joint venture between Reef Group and UBS). The property is a 70,000 square foot purpose built GMP manufacturing facility in Stevenage. .
Practice head
The lawyer(s) leading their teams.
James Fry